Testicular Cancer, Version 2.2015

被引：90

作者：

Motzer, Robert J. ^{[1
,2
]}

Jonasch, Eric ^{[3
]}

Agarwal, Neeraj ^{[4
]}

Beard, Clair ^{[5
,6
]}

Bhayani, Sam ^{[7
]}

Bolger, Graeme B. ^{[8
]}

Chang, Sam S. ^{[9
,10
]}

Choueiri, Toni K. ^{[11
]}

Costello, Brian A. ^{[12
]}

Derweesh, Ithaar H. ^{[13
]}

Gupta, Shilpa ^{[14
,15
]}

Hancock, Steven L. ^{[16
]}

Kim, Jenny J. ^{[17
]}

Kuzel, Timothy M. ^{[18
]}

Lam, Elaine T. ^{[19
]}

Lau, Clayton ^{[20
]}

Levine, Ellis G. ^{[21
]}

Lin, Daniel W. ^{[22
]}

Michaelson, M. Dror ^{[23
]}

Olencki, Thomas ^{[24
,25
]}

Pili, Roberto ^{[21
]}

Plimack, Elizabeth R. ^{[26
]}

Rampersaud, Edward N. ^{[27
]}

Redman, Bruce G. ^{[28
]}

Ryan, Charles J. ^{[29
,30
]}

Sheinfeld, Joel ^{[31
]}

Shuch, Brian ^{[32
]}

Sircar, Kanishka ^{[33
]}

Somer, Brad ^{[34
]}

Wilder, Richard B. ^{[35
]}

Dwyer, Mary

Kumar, Rashmi

机构：

[1] Mem Sloan Kettering Canc Ctr, Med Oncol, New York, NY USA

[2] Univ Texas MD Anderson Canc Ctr, Med Oncol, Houston, TX USA

[3] Mem Sloan Kettering Canc Ctr, Internal Med, New York, NY USA

[4] Univ Utah, Huntsman Canc Inst, Hematol Hematol Oncol, Salt Lake City, UT 84112 USA

[5] Dana Farber Brigham & Womens Canc Ctr, Radiat Oncol, Boston, MA USA

[6] Barnes Jewish Hosp, Siteman Canc Ctr, Urol, St Louis, MO USA

[7] Washington Univ, Sch Med, Urol, St Louis, MO 63130 USA

[8] Univ Alabama Birmingham, Ctr Comprehens Canc, Med Oncol, Birmingham, AL USA

[9] Vanderbilt Ingram Canc Ctr, Urol, Nashville, TN USA

[10] Dana Farber Brigham & Womens Canc Ctr, Med Oncol, Boston, MA USA

[11] Dana Farber Brigham & Womens Canc Ctr, Internal Med, Boston, MA USA

[12] Mayo Clin, Ctr Canc, Med Oncol, Rochester, MN USA

[13] UC San Diego Moores Canc Ctr, Urol, San Diego, CA USA

[14] H Lee Moffitt Canc Ctr & Res Inst, Med Oncol, Tampa, FL USA

[15] Stanford Canc Inst, Radiat Oncol, Stanford, CA USA

[16] Stanford Canc Inst, Internal Med, Stanford, CA USA

[17] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Med Oncol, Baltimore, MD USA

[18] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Hematol Hematol Oncol, Evanston, IL 60208 USA

[19] Univ Colorado, Ctr Canc, Med Oncol, Boulder, CO 80309 USA

[20] City Hope Comprehens Canc Ctr, Urol, Duarte, CA USA

[21] Roswell Pk Canc Inst, Med Oncol, Buffalo, NY USA

[22] Univ Washington, Seattle Canc Care Alliance, Urol, Seattle, WA 98195 USA

[23] Massachusetts Gen Hosp, Ctr Canc, Med Oncol, Boston, MA 02114 USA

[24] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Med Oncol, Columbus, OH 43210 USA

[25] Solove Res Inst, Med Oncol, Columbus, OH USA

[26] Fox Chase Canc Ctr, Med Oncol, Philadelphia, PA USA

[27] Duke Canc Inst, Urol, Durham, NC USA

[28] Univ Michigan, Ctr Comprehens Canc, Med Oncol, Ann Arbor, MI 48109 USA

[29] UCSF Helen Diller Family Comprehens Canc Ctr, Med Oncol, San Francisco, CA USA

[30] UCSF Helen Diller Family Comprehens Canc Ctr, Urol, San Francisco, CA USA

[31] Mem Sloan Kettering Canc Ctr, Urol, New York, NY USA

[32] Smilow Canc Hosp, Yale Canc Ctr, Urol, New Haven, CT USA

[33] Univ Texas MD Anderson Canc Ctr, Pathol, Houston, TX USA

[34] Univ Tennessee, Hlth Sci Ctr, St Jude Childrens Res Hosp, Med Oncol, Knoxville, TN 37996 USA

[35] H Lee Moffitt Canc Ctr & Res Inst, Radiat Oncol, Tampa, FL USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2015年 / 13卷 / 06期

关键词：

GERM-CELL TUMORS; CLINICAL STAGE-I; POSITRON-EMISSION-TOMOGRAPHY; LYMPH-NODE DISSECTION; HIGH-DOSE CHEMOTHERAPY; TERM-FOLLOW-UP; GEMCITABINE SALVAGE CHEMOTHERAPY; POSTCHEMOTHERAPY RESIDUAL MASS; CISPLATIN-BASED CHEMOTHERAPY; COOPERATIVE-ONCOLOGY-GROUP;

D O I：

10.6004/jnccn.2015.0092

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Germ cell tumors (GCTs) account for 95% of testicular cancers. Testicular GCTs constitute the most common solid tumor in men between the ages of 20 and 34 years, and the incidence of testicular GCTs has been increasing in the past 2 decades. Testicular GCTs are classified into 2 broad groups-pure seminoma and nonseminoma-which are treated differently. Pure seminomas, unlike nonseminomas, are more likely to be localized to the testis at presentation. Nonseminoma is the more clinically aggressive tumor associated with elevated serum concentrations of alphafetoprotein (AFP). The diagnosis of a seminoma is restricted to pure seminoma histology and a normal serum concentration of AFP. When both seminoma and elements of a nonseminoma are present, management follows that for a nonseminoma. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Testicular Cancer outline the diagnosis, workup, risk assessment, treatment, and follow-up schedules for patients with both pure seminoma and nonseminoma.

引用

页码：772 / 798

页数：27

共 172 条

[1] Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers
Albers, P
Ganz, A
Hannig, E
Miersch, MDE
Müller, SC
[J]. JOURNAL OF UROLOGY, 2000, 164 (02) : 381 - 384
[2] Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors
Albers, P
Bender, H
Yilmaz, H
Schoeneich, G
Biersack, HJ
Mueller, SC
[J]. UROLOGY, 1999, 53 (04) : 808 - 811
[3] Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German testicular cancer study group
Albers, Peter
Siener, Roswitha
Krege, Susanne
Schmelz, Hans-Uwe
Dieckmann, Klaus-Peter
Heidenreich, Axel
Kwasny, Peter
Pechoel, Maik
Lehmann, Jan
Kliesch, Sabine
Koehrmann, Kai-Uwe
Fimmers, Rolf
Weissbach, Lothar
Loy, Volker
Wittekind, Christian
Hartmann, Michael
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (18) : 2966 - 2972
[4] [Anonymous], P ANN SOC CLIN ONCOL
[5] [Anonymous], SEER stat fact sheets
[6] [Anonymous], 2003, APMIS
[7] [Anonymous], J CLIN ONCOL
[8] [Anonymous], TRIAL IM SCHED SEM T
[9] Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma
Aparicio, J
del Muro, XG
Maroto, P
Paz-Ares, L
Alba, E
Sáenz, A
Terrasa, J
Barnadas, A
Almenar, D
Arranz, JA
Sánchez, M
Fernández, A
Sastre, J
Carles, J
Dorca, J
Gumà, J
Yuste, AL
Germà, JR
[J]. ANNALS OF ONCOLOGY, 2003, 14 (06) : 867 - 872
[10] Risk-adapted management for patients with clinical stage I seminoma:: The second Spanish germ cell cancer cooperative group study
Aparicio, J
Germà, JR
del Muro, XG
Maroto, P
Arranz, JA
Sáenz, A
Barnadas, A
Dorca, J
Gumà, J
Olmos, D
Bastús, R
Carles, J
Almenar, D
Sánchez, M
Paz-Ares, L
Satrústegui, JJ
Mellado, B
Balil, A
López-Brea, M
Sánchez, A
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) : 8717 - 8723

← 1 2 3 4 5 6 7 8 9 10 →